Skip To The Main Content
2020RapidMicro-1988x680

2020 PDA Rapid Microbiological Methods Workshop

Oct 22 - Oct 23, 2020
Eastern Standard Time | Online
  • Virtual
  • Conference
  • Online
  • The Americas

Overview

As the pharmaceutical industry continues its fast-moving evolution, the focus on new technologies intensifies. The validation, approval, and implementation of rapid and alternative microbiological methods has also been steadily increasing within the pharmaceutical, biopharmaceutical, compounding pharmacy, and advanced therapy medicinal products (ATMP, gene and cell therapy) industries. Novel drug products and innovative manufacturing processes now require modern strategies for demonstrating microbiological control.

Attend the 2020 PDA Rapid Microbiological Methods Workshop virtually to gain meaningful insight and practical lessons learned from actual success stories on important issues currently facing the industry. Explore the current landscape for rapid method validation strategies, implementation opportunities, and global regulatory approval processes. Presentations by subject matter experts and global regulators will focus on real-world practices for rapid and alternative microbiology testing of in-process samples and sterile and nonsterile finished product.

This Workshop will present practical approaches to rapid microbiology testing that participants can use in daily work, laboratory, and manufacturing operations.

Agenda

  • Day 1
  • Day 2
  • Thursday, October 22

    10:00 a.m. – 11:45 a.m. | P1: Case Studies on Method Suitability and Validation
    Moderator: Erika A. Pfeiler, PhD, Supervisory Microbiologist, CDER, U.S. FDA

    We have all heard so much about the barriers to adopting rapid microbiological methods – technological issues, expense, regulatory compliance – so why should the microbiologists take on the hassle of advocating for them in their organizations? This session highlights the expanding usefulness of rapid methods to demonstrate microbiological quality for a variety of products. The speakers have each dealt with and overcome the barriers to adoption, worked towards successful implementation of a rapid method, and are here to share their experiences.

    10:00 a.m. – 10:15 a.m. | Welcome and Opening Remarks
    Amy L. McDaniel, PhD, Director, Microbial Center of Excellence & Operations, Bristol-Myers Squibb

    10:15 a.m. – 10:30 a.m. | What is Rapid Microbiological Methods and Why is it Important
    Michael J. Miller, PhD, President, Microbiology Consultants, LLC

    10:30 a.m. – 10:50 a.m. | Demonstrating Method Suitability for an ATP-bioluminescence Rapid Method for Egg-Based Vaccine Testing
    Stacey N. Ramsey, MS, SM(NRCM), Associate Product Manager, Charles River Laboratories

    10:50 a.m. – 11:10 a.m. | Evolution of an Automated Rapid Microbial Testing Technology to Satisfy Pharmaceutical Requirements
    Lori L. Daane, PhD, Director of Scientific Affairs, bioMérieux, Inc.

    11:10 a.m. – 11:30 p.m. | Validation and Global Implementation of an Alternative Sterility Test
    Sven M. Deutschmann, PhD,
    Head of Global Analytical Science & Technology "Adventitious Agents Testing & Alternative Microbiological Methods", Global QC, Roche Diagnostics GmbH

    11:30 a.m. – 11:45 a.m. | Q&A

    11:45 a.m. – 12:05 p.m. | Break

    12:05 p.m. – 1:30 p.m. | P2: Expecting the Unexpected: Overcoming the Challenges of Rapid Testing
    Moderator: Andrew D. Hopkins, BSc Hon PGDip, Director, Operation Quality QA Audit and Compliance, AbbVie, Inc.

    This session is a great opportunity to hear from both industry specialists (at the sharp end) and the regulators. Case studies will be used to show some of the challenges (and opportunities) that arise when introducing rapid micro methods. The first case study will discuss sampling and the use of rapid sterility tests, next we will have a presentation on the challenges of OOT and aberrant results when using rapid micro methods and then finally, we will be given an opportunity to hear firsthand some of the issues that the regulators see when companies introduce rapid technology. A great opportunity to learn from others and even perhaps even safe you having to deal with the same challenges if you are introducing rapid methods.

    12:05 p.m. – 12:25 p.m. | STAT Results for STAT Samples: Implementing Modern Rapid Micro Methods
    Wayne I. DeHaven, PhD,
    Director, Pharmetric Lab

    12:25 p.m. – 12:45 p.m. | Challenges Associated with Interpreting Aberrant/OOT Results Obtained from Rapid Microbiology Method for Detection of Mycoplasma Using Real-time Polymerase Chain Reaction for Release of Cell Therapy Products
    D. Marissa Mistry,
    Senior Scientist, Bristol-Myers Squibb

    12:45 p.m. – 1:05 p.m. | An FDA Perspective on Rapid Micro Methods in the Pharmaceutical Industry
    Bryan S. Riley, PhD, Branch Chief, CDER, U.S. FDA

    1:05 p.m. – 1:30 p.m. | Q&A

  • Friday, October 23

    10:00 a.m. – 11:15 a.m. | P3: New Developments in Rapid Method Technologies
    Moderator: Michael J. Miller, PhD, President, Microbiology Consultants, LLC.

    Recent developments in rapid method scientific principles will be the focus of this session, as we explore new opportunities in miniaturization, automation and sensitivity. We will learn about a novel viability staining and Raman spectroscopy technique that provides quantitative and microbial identification results at the same time. Next, a miniaturized RT-PCR platform for the rapid detection of Mycoplasma will be discussed. Finally, we will hear about the development of a novel ATP bioluminescence system with single cell detection without the need for an enrichment step.

    10:00 a.m. – 10:20 a.m. | Microbes as Analytes: Evaluating Raman Based Chemometrics for Quality Release
    Kevin I. Wright, PhD,
    Director, Corporate Quality Assurance - Industrial Microbiology, Procter & Gamble Techical Centres Ltd.

    10:20 a.m. – 10:40 a.m. | Shaping the Future of Mycoplasma Testing – Evaluation of a New Automated and Rapid PCR-based Technology
    Alex Z. van der Meer, MSc, Specialist Mycoplasma Testing, Janssen Biologicals

    10:40 a.m. – 11:00 a.m. | Cultivation-free ATP RMM System and its Evaluation Based on Method Validation Criteria and Implementation in Pharmaceutical Water System
    Yoko Nakaim, MS Engineering, Manager, HORIBA Advanced Techno, Co., Ltd.

    11:00 a.m. – 11:15 a.m. | Q&A

    11:15 a.m. – 11:35 a.m. | Break

    11:35 a.m. – 12:45 p.m. | P4: Ask the Experts and Regulators
    Moderator: Josh E. Eaton, MS, Assistant Director, Scientific Affairs, PDA

    Industry experts and regulators join together to discuss applications and options for incorporating rapid microbiology methods across a variety of product classes. The panel will address some common issues regarding the technologies and their implementation and will also tackle attendee submitted questions. This is a prime opportunity to take advantage of their experience and perspectives to help guide your decision processes.

    11:35 a.m. – 12:35 p.m. | Industry and Regulatory Round Table
    Frederic B. Ayres, Research Scientist, Eli Lilly and Company
    Michael N. Blackton, MBA, Vice President, Quality, Adaptimmune LLC
    CDR James L. Kenney, DSc, Chief, LMIVTS, CBER, U.S. FDA
    Bryan S. Riley, PhD, Branch Chief, CDER, U.S. FDA
    Kevin I. Wright, PhD, Director, Corporate Quality Assurance - Industrial Microbiology, Procter & Gamble Techical Centres Ltd.

    12:35 p.m. – 12:45 p.m. | Closing Remarks


Highlighted Speakers

Lori L. Daane
Lori L. Daane
bioMérieux
Irving Ford
Irving Ford
Bristol-Myers Squibb
CDR James L. Kenney
CDR James L. Kenney
U.S. FDA
Michael J. Miller
Michael J. Miller
Microbiology Consultants, LLC
Yoko Nakai
Yoko Nakai
HORIBA Advanced Techno, Co., Ltd.
Erika A. Pfeiler
Erika A. Pfeiler
U.S. FDA
Stacey N. Ramsey
Stacey N. Ramsey
Charles River Laboratories
Kevin I. Wright
Kevin I. Wright
Procter & Gamble Technical Centres Ltd.

Who Should Attend

  • Departments: Microbiology, Compliance, Engineering, Manufacturing, QA/QC, CMC Documentation, Regulatory Affairs, Research and Development, Validation, QP
  • Level of Expertise: Senior Management, Scientists/Technicians
  • Job Function: Supervisor, Researcher, Analyst, Operative Personnel

Registration Fees

Register Now
Registration Type Fee
Member $1,196
Non-member $1,475
Young Professional Member $598
Gov’t/Health Auth./Academic Member $560
Gov’t/Health Auth./Academic Non-member* $640
Student Member $248
Student Non-member* $224

Got a Question? We have answers

Contact Us
Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information

Exhibitors

Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Media Partners

Related Events

Contact

Program Inquiries
Exhibition Inquiries
Course Inquiries
Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]

PDA Members Save Substantially